Assessing the “value” of new drugs in the treatment of [prostate] cancer

Yesterday the American Society of Clinical Oncology (ASCO) issued the initial draft of “a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.” ASCO is interested in getting feedback from its members and from the patient community too. … READ MORE …

Another new way to diagnose prostate cancer more accurately?

A news item on Friday in the Rochester Democrat and Chronicle describes research ongoing at the Rochetster Institute of Technology into another new way to identify men at high risk for prostate cancer — but using targeted dying agents that will “stick” to the membranes of prostate cancer cells. … READ MORE …

The complexity of assessment of prostate cancer risk

A new study just published online in the journal Cancer Discovery has helped to clarify — or perhaps “clarify” is the wrong word — just how complex risk for prostate cancer really is. … READ MORE …

Astellas, Medivation initiate TRUMPET registry study

Many patients newly diagnosed with castration-resistant prostate cancer (CRPC) may be interested in participating in a new registry study known as the TRUMPET study, which has just started to enroll patients and is sponsored by Astellas and Medivation (the developers and marketers of enzalutamide/Xtandi). … READ MORE …

Major trial confirms value of zoledronic acid dosed every 3 months in preventing pain, SREs

An interesting paper that we managed to miss at the recent annual meeting of the American Society of Clinical Oncology (ASCO) provided the results of a large, randomized clinical trial of the use of zoledronic acid, carried out by the Cancer and Leukemia Group B cooperative trial group. … READ MORE …

The NCCN patient guidelines have “come of age”

Over the past weekend, we were able to review the most recent update to the National Comprehensive Cancer Network’s guidelines on treatment of prostate cancer for patients. It is our considered opinion that this booklet is now among the very best basic introductions to prostate cancer management for any newly diagnosed patient and his family. … READ MORE …

Are you an “Illustrated Man”?

Heavily tattooed men with prostate cancer should be aware that there is a low risk — and probably only a very low risk indeed — that tattoo ink can migrate to the pelvic lymph nodes leading to misdiagnosis of node-positive prostate cancer when such patients are given PET/CT scans. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,320 other followers